Idorsia Ltd (IDIA.SW)
CHF 1.3
(2.45%)
CHF 1.3
(2.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 145.23 Million CHF | 38.93% |
| 2022 | 90.83 Million CHF | 424.58% |
| 2021 | 17.31 Million CHF | 105.6% |
| 2020 | -309.31 Million CHF | 25.41% |
| 2019 | -414.7 Million CHF | -34.01% |
| 2018 | -309.46 Million CHF | -8026.28% |
| 2017 | -3.8 Million CHF | 78.98% |
| 2016 | -18.12 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 11.03 Million CHF | -31.48% |
| 2024 Q1 | 2.68 Million CHF | -84.26% |
| 2024 Q2 | 11.28 Million CHF | 320.13% |
| 2023 Q3 | 78.47 Million CHF | 206.91% |
| 2023 FY | 126.2 Million CHF | 38.93% |
| 2023 Q1 | 20.17 Million CHF | -61.08% |
| 2023 Q2 | 25.56 Million CHF | 26.75% |
| 2023 Q4 | 17.07 Million CHF | -78.25% |
| 2022 Q3 | 17.99 Million CHF | 59.2% |
| 2022 FY | 90.83 Million CHF | 424.58% |
| 2022 Q4 | 51.83 Million CHF | 188.07% |
| 2022 Q2 | 11.3 Million CHF | 125688.89% |
| 2022 Q1 | -9000.00 CHF | -101.44% |
| 2021 FY | 17.31 Million CHF | 105.6% |
| 2021 Q4 | 625 Thousand CHF | 100.79% |
| 2021 Q3 | -79.31 Million CHF | 9.19% |
| 2021 Q2 | -87.34 Million CHF | 3.58% |
| 2021 Q1 | -90.58 Million CHF | -5.75% |
| 2020 FY | -309.31 Million CHF | 25.41% |
| 2020 Q3 | -85.14 Million CHF | -82.04% |
| 2020 Q1 | -91.74 Million CHF | 14.69% |
| 2020 Q2 | -46.77 Million CHF | 49.02% |
| 2020 Q4 | -85.66 Million CHF | -0.61% |
| 2019 Q2 | -103.64 Million CHF | -0.67% |
| 2019 Q1 | -102.95 Million CHF | -22.89% |
| 2019 FY | -414.7 Million CHF | -34.01% |
| 2019 Q4 | -107.54 Million CHF | -6.93% |
| 2019 Q3 | -100.57 Million CHF | 2.96% |
| 2018 Q3 | -99.67 Million CHF | -52.44% |
| 2018 Q1 | -60.63 Million CHF | -166.29% |
| 2018 FY | -309.46 Million CHF | -8026.28% |
| 2018 Q4 | -83.77 Million CHF | 15.95% |
| 2018 Q2 | -65.38 Million CHF | -7.83% |
| 2017 FY | -3.8 Million CHF | 78.98% |
| 2017 Q1 | -90.88 Million CHF | 0.0% |
| 2017 Q2 | 82.64 Million CHF | 190.94% |
| 2017 Q4 | 91.47 Million CHF | 265.03% |
| 2017 Q3 | -55.42 Million CHF | -167.07% |
| 2016 FY | -18.12 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Addex Therapeutics Ltd | -5.31 Million CHF | 2830.874% |
| BB Biotech AG | -199.56 Million CHF | 172.776% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | -11.003% |
| Evolva Holding SA | -2.58 Million CHF | 5723.635% |
| Kuros Biosciences AG | 22.87 Million CHF | -534.995% |
| Molecular Partners AG | -40.8 Million CHF | 455.918% |
| Relief Therapeutics Holding AG | -10.85 Million CHF | 1437.471% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | -45.901% |